• If you are wondering whether Veeva Systems at around US$155.97 is starting to look attractively priced, you are not alone.
• The share price has been under pressure, with a 0.1% slip over the past week, an 11.2% decline over 30 days, a 28.9% decline year to date, and a 32.8% decline over the last year.
• Recent headlines have focused on how Veeva Systems is positioned within healthcare software and its ability to support life sciences companies with regulated data and workflows. This context helps explain why the stock can react sharply when news shifts expectations around customer adoption or competitive positioning.
• Simply Wall St currently gives Veeva Systems a valuation score of 4 out of 6. The next step is to unpack what different valuation methods say about that number and then consider an even more complete way to think about value at the end of this article.

Approach 1: Veeva Systems Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business might be worth by projecting its future cash flows and then discounting those back to today’s value. It is essentially asking what all those future dollars are worth in today’s terms.

For Veeva Systems, the model used here is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections. The latest twelve month Free Cash Flow is around $1.39b. Analyst inputs and subsequent extrapolations by Simply Wall St feed into ten year projections, with forecast Free Cash Flow for 2031 of about $2.43b. Beyond the initial analyst horizon, later years are extended using estimated growth rates rather than new analyst forecasts.

When those projected cash flows are discounted back, the DCF model arrives at an estimated intrinsic value of about $271.59 per share. Against the recent share price of around $155.97, this implies Veeva Systems trades at roughly a 42.6% discount to this intrinsic estimate. This indicates that the shares appear undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Veeva Systems is undervalued by 42.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Veeva Systems Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand because it links what you pay today to the earnings the business is already generating. Investors typically accept a higher or lower P/E depending on how they see the balance between growth potential and risk, which together shape what feels like a “normal” or “fair” multiple for a stock.

Veeva Systems currently trades on a P/E of about 28.0x. That is very close to the Healthcare Services industry average P/E of 28.1x and the peer average of 27.8x, so on simple comparisons the stock sits roughly in line with its sector.

Simply Wall St’s Fair Ratio for Veeva Systems is 28.6x. This is a proprietary estimate of the P/E that might be expected given factors such as earnings growth, profit margin, market cap, risk profile and the Healthcare Services industry context. Because it pulls these elements together in one number, the Fair Ratio can be more tailored than a basic peer or industry comparison.

Comparing the Fair Ratio of 28.6x with the current P/E of 28.0x suggests the shares look about right on this metric.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Veeva Systems Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives offer that by letting you set out your own story for Veeva Systems, link that story to specific revenue, earnings and margin assumptions, tie those to a Fair Value, and then compare that Fair Value with the current share price using an easy tool on Simply Wall St’s Community page that updates as new news or earnings arrive. One investor might build a bullish Veeva view anchored around a Fair Value near US$380 based on higher growth and margins, while another might lean on a more cautious Fair Value near US$232.80. Each of those Narratives then becomes a clear, numbers backed explanation of why VEEV looks attractive, fully priced or somewhere in between to that particular investor.

Do you think there's more to the story for Veeva Systems? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.